Bank of Montreal Can Purchases 2,133,606 Shares of Eli Lilly and Co (LLY)

Bank of Montreal Can lifted its position in shares of Eli Lilly and Co (NYSE:LLY) by 85.4% in the 4th quarter, Holdings Channel reports. The fund owned 4,631,241 shares of the company’s stock after buying an additional 2,133,606 shares during the period. Bank of Montreal Can’s holdings in Eli Lilly and were worth $391,156,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Accredited Investors Inc. lifted its holdings in Eli Lilly and by 0.4% in the second quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock worth $268,000 after purchasing an additional 14 shares during the period. Oakworth Capital Inc. lifted its holdings in Eli Lilly and by 0.3% in the second quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock worth $552,000 after purchasing an additional 20 shares during the period. Sfmg LLC lifted its holdings in Eli Lilly and by 0.5% in the second quarter. Sfmg LLC now owns 4,258 shares of the company’s stock worth $350,000 after purchasing an additional 20 shares during the period. Jackson Grant Investment Advisers Inc. lifted its holdings in Eli Lilly and by 0.7% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,647 shares of the company’s stock worth $300,000 after purchasing an additional 24 shares during the period. Finally, YorkBridge Wealth Partners LLC lifted its holdings in Eli Lilly and by 0.8% in the second quarter. YorkBridge Wealth Partners LLC now owns 3,199 shares of the company’s stock worth $265,000 after purchasing an additional 24 shares during the period. Institutional investors and hedge funds own 76.35% of the company’s stock.

Shares of Eli Lilly and Co (NYSE LLY) traded down $1.69 during midday trading on Tuesday, reaching $85.29. 4,772,240 shares of the company’s stock were exchanged, compared to its average volume of 2,944,430. Eli Lilly and Co has a 52 week low of $74.00 and a 52 week high of $89.09. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. The firm has a market cap of $93,910.00, a P/E ratio of 40.61, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The firm had revenue of $5.66 billion for the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.88 EPS. sell-side analysts anticipate that Eli Lilly and Co will post 4.22 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a yield of 2.64%. The ex-dividend date of this dividend is Wednesday, February 14th. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s payout ratio is presently 99.05%.

Several equities research analysts recently weighed in on the stock. Jefferies Group set a $100.00 price objective on shares of Eli Lilly and and gave the stock a “buy” rating in a report on Tuesday. Goldman Sachs Group downgraded shares of Eli Lilly and from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $86.98 to $95.00 in a report on Tuesday. BMO Capital Markets reissued a “sell” rating and issued a $71.00 price target on shares of Eli Lilly and in a report on Thursday, September 28th. Cowen reissued a “buy” rating and issued a $95.00 price target on shares of Eli Lilly and in a report on Wednesday, October 4th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $105.00 price target on shares of Eli Lilly and in a report on Friday, October 13th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $92.75.

In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of the business’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the sale, the senior vice president now owns 43,580 shares in the company, valued at approximately $3,646,338.60. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the business’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $88.20, for a total value of $17,640,000.00. Following the sale, the insider now owns 123,084,104 shares in the company, valued at approximately $10,856,017,972.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 251,088 shares of company stock worth $22,041,236. Corporate insiders own 0.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Bank of Montreal Can Purchases 2,133,606 Shares of Eli Lilly and Co (LLY)” was published by BBNS and is the property of of BBNS. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://baseballnewssource.com/markets/bank-of-montreal-can-purchases-2133606-shares-of-eli-lilly-and-co-lly/1840408.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with our FREE daily email newsletter.

 


Latest News

Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
Trade Rumor: Manny Machado Could Land With Yankees
Trade Rumor: Manny Machado Could Land With Yankees


Leave a Reply

 
© 2006-2018 BBNS.